Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 15.

Journal Article

Christgen, Matthias, Gluz, Oleg, Harbeck, Nadia, Kates, Ronald E., Raap, Mieke, Christgen, Henriette, Clemens, Michael, Malter, Wolfram, Nuding, Benno, Aktas, Bahriye, Kuemmel, Sherko, Reimer, Toralf, Stefek, Andrea, Krabisch, Petra, Just, Marianne, Augustin, Doris, Graeser, Monika, Baehner, Frederick, Wuerstlein, Rachel, Nitz, Ulrike and Kreipe, Hans (2020). Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer. Cancer, 126 (22). S. 4847 - 4859. HOBOKEN: WILEY. ISSN 1097-0142

Degenhardt, Tom, Kreipe, Hans Heinrich, Gluz, Oleg, Kates, Ronald E., Liedtke, Cornelia, Kraemer, Stefan, Clemens, Michael R., Nuding, Benno, Reimer, Toralf, Aktas, Bahriye, Kummel, Sherko, Just, Marianne, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Stefek, Andrea, Heyl, Volker, Wuerstlein, Rachel, Nitz, Ulrike, Harbeck, Nadia and Christgen, Matthias (2016). Prognostic impact of androgen receptor (AR) and forkhead box A1 (FOXA1) in early HER2-negative primary breast cancer: A translational substudy of the prospective phase III WSG-PlanB-trial. J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Gluz, Oleg, Kolberg-Liedtke, Cornelia, Prat, Aleix ORCID: 0000-0003-2377-540X, Christgen, Matthias, Gebauer, Daniel, Kates, Ronald, Pare, Laia ORCID: 0000-0002-4904-558X, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Kuemmel, Sherko, Wuerstlein, Rachel, Pelz, Enrico, Nitz, Ulrike, Kreipe, Hans Heinrich and Harbeck, Nadia (2020). Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial. Int. J. Cancer, 146 (1). S. 262 - 272. HOBOKEN: WILEY. ISSN 1097-0215

Gluz, Oleg, Liedtke, Cornelia, Prat, Aleix, Christgen, Matthias, Gebauer, Daniel, Kates, Ronald, Pelz, Enrico, Clemens, Michael, Warm, Matthias, Aktas, Bahriye, Kuemmel, Sherko, Pare, Laia, Krabisch, Petra, Kreipe, Hans Heinrich, Wuerstlein, Rachel, Nitz, Ulrike and Harbeck, Nadia (2018). Genomic markers but not molecular subtypes provide prognostic impact and predict anthracycline efficacy in early triple-negative breast cancer: Results from the prospective WSG PlanB trial. Cancer Res., 78 (4). PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Gluz, Oleg, Nitz, Ulrike, Christgen, Matthias, Kates, Ronald E., Clemens, Michael, Kraemer, Stefan, Nuding, Benno, Reimer, Toralf, Aktas, Bahriye, Kummel, Sherko, Just, Marianne, Stefek, Andrea, Lorenz-Salehi, Fatemeh, Krabisch, Petra, Liedtke, Cornelia, Svedman, Christer, Shak, Steven, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Harbeck, Nadia (2016). Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2-early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial. J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Gluz, Oleg, Nitz, Ulrike, Liedtke, Cornelia, Christgen, Matthias, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Bangemann, Nikola, Lindner, Christoph, Kuemmel, Sherko, Clemens, Michael, Potenberg, Jochem, Staib, Peter, Kohls, Andreas, von Schumann, Raquel and Harbeck, Nadia (2018). Comparison of Neoadjuvant Nab-Paclitaxe plus Carboplatin vs Nab-Paclitaxe plus Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results. JNCI-J. Natl. Cancer Inst., 110 (6). S. 628 - 638. CARY: OXFORD UNIV PRESS INC. ISSN 1460-2105

Gluz, Oleg, Nitz, Ulrike A., Christgen, Matthias, Kates, Ronald E., Shak, Steven, Clemens, Michael, Kraemer, Stefan, Aktas, Bahriye, Kuemmel, Sherko, Reimer, Toralf, Kusche, Manfred, Heyl, Volker, Lorenz-Salehi, Fatemeh, Just, Marianne, Hofmann, Daniel, Degenhardt, Tom, Liedtke, Cornelia, Svedman, Christer, Wuerstlein, Rachel, Kreipe, Hans H. and Harbeck, Nadia (2016). West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. J. Clin. Oncol., 34 (20). S. 2341 - 2353. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Harbeck, Nadia, Gluz, Oleg, Christgen, Matthias, Kates, Ronald Ernest, Braun, Michael, Kueemmel, Sherko, Schumacher, Claudia, Potenberg, Jochem, Kraemer, Stefan, Kleine-Tebbe, Anke, Augustin, Doris, Aktas, Bahriye, Forstbauer, Helmut, Tio, Joke, von Schumann, Raquel, Liedtke, Cornelia, Grischke, Eva-Maria, Schumacher, Johannes, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Nitz, Ulrike Anneliese (2017). De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2-and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. J. Clin. Oncol., 35 (26). S. 3046 - 3057. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Harbeck, Nadia, Gluz, Oleg, Clemens, Michael R., Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kummel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald, Kreipe, Hans Heinrich and Nitz, Ulrike (2017). Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC -> 4x doc vs. 6x docetaxel/cyclophospham ide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer. J. Clin. Oncol., 35. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Harbeck, Nadia, Nitz, Ulrike, Christgen, Matthias, Kates, Ronald E., Braun, Michael Wilhelm, Kummel, Sherko, Schumacher, Claudia, Potenberg, Jochem, Malter, Wolfram, Augustin, Doris, Aktas, Bahriye, Forstbauer, Helmut, Tio, Joke, Kleine-Tebbe, Anke, Liedtke, Cornelia, de Haas, Sanne, Deurloo, Regula, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Gluz, Oleg (2018). Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Nitz, Ulrike, Gluz, Oleg, Christgen, Matthias, Kates, Ronald E., Clemens, Michael, Malter, Wolfram, Nuding, Benno, Aktas, Bahriye, Kuemmel, Sherko, Reimer, Toralf, Stefek, Andrea, Lorenz-Salehi, Fatemeh, Krabisch, Petra, Just, Marianne, Augustin, Doris, Liedtke, Cornelia, Chao, Calvin, Shak, Steven, Wuerstlein, Rachel, Kreipe, Hans H. and Harbeck, Nadia (2017). Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. Breast Cancer Res. Treat., 165 (3). S. 573 - 584. NEW YORK: SPRINGER. ISSN 1573-7217

Nitz, Ulrike, Gluz, Oleg, Clemens, Michael, Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kuemmel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald E., Kreipe, Hans H., Harbeck, Nadia, Ackermann, S., Aktas, B., Augustin, D., Baake, G., Baumann, K., Berger, R., Bettscheider, J., Bischoff, J., Clemens, M., Deryal, M., Dubbers, H., Duchting, D., Dunnebacke, J., Fett, W., Fietz, T., Fischer, H., Forner, M., Forstbauer, H., Freese, K., Geberth, M., Glados, M., Gnauert, K., Goette, O., Gohring, U., Goppinger, A., Grafe, A., Hackenberg, R., Hackmann, J., Hellriegel, M., Heyl, V., Hoestermann, C., Hoffmann, G., Hofmann, M., Hucke, J., Jackisch, C., Jungberg, P., Just, M., Kahl, C., Klare, P., Kogel, M., Kohls, A., Amrawy, B. Konigs-El, Konnecke, P., Krabisch, P., Kraudelt, S., Kremers, S., Kummel, S., Kurbacher, C., Kusche, J., Liedtke, B., Liedtke, C., Link, H., Lorenz, R., Salehi, F. Lorenz, Lubbe, K., Malter, W., Melekian, B., Mobus, V., Montenarh, M., Mueller, V., Mundhenke, C., Niederle, N., Nitz, U., Noesselt, T., Oberhoff, C., Paas, L., Paepke, S., Pollmanns, A., Reichert, D., Reimer, T., Romann, D., Ruhland, T., Runde, V., Salem, M., Schlosser, A., Schneider, A., Schrader, I., Schulz, H., Schumacher, C., Schwickerath, J., Soling, U., Stauder, H., Stefek, A., Steinmetz, T., Stickeler, E., Terhaag, J., Thomssen, C., Tome, O., Uleer, C., Warm, M., Wachsmann, G., Wacker, J., Wiebringhaus, H., Wiest, W., Wolfgarten, M., Nitz, U., Christgen, H., Kreipe, H., Buehne, C., Gluz, O., Hansen, K., Hofmann, D., Kates, R., Mangold, M., Mathissen, M., Raeth, P., Renner, I., Reiser, I., Schumacher, J., Staedele, M. and Walter-Kirst, R. (2019). West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. J. Clin. Oncol., 37 (10). S. 799 - 811. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Nitz, Ulrike, Gluz, Oleg, Kreipe, Hans H., Christgen, Matthias, Kuemmel, Sherko, Baehner, Frederick L., Shak, Steven, Aktas, Bahriye, Braun, Michael, Ludtke-Heckenkamp, Kerstin, Forstbauer, Helmut, Grischke, Eva-Maria, Nuding, Benno, Darsow, Maren, Schumacher, Claudia, Krauss, Katja, Malter, Wolfram, Thill, Marc, Warm, Mathias, Wuerstlein, Rachel, Kates, Ronald E. and Harbeck, Nadia (2020). The run-in phase of the prospective WSG-ADAPT HR+/HER2-trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer. Ther. Adv. Med. Oncol., 12. LONDON: SAGE PUBLICATIONS LTD. ISSN 1758-8359

Schneeweiss, Andreas, Jackisch, Christian, Schmatloch, Sabine, Aktas, Bahriye, Denkert, Carsten, Schem, Christian, Wiebringhaus, Hermann, Kummel, Sherko, Rhiem, Kerstin, Warm, Mathias, Fasching, Peter A., Just, Marianne, Hanusch, Claus, Hackmann, John, Blohmer, Jens Uwe, Gerber, Bernd, Furlanetto, Jenny, von Minckwitz, Gunter, Nekljudova, Valentina, Loibl, Sibylle and Untch, Michael (2018). Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer-GBG69. Cancer Res., 78 (4). PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Untch, Michael, Jackisch, Christian, Schneeweiss, Andreas, Schmatloch, Sabine, Aktas, Bahriye, Denkert, Carsten, Schem, Christian, Wiebringhaus, Hermann, Kuemmel, Sherko, Warm, Mathias, Fasching, Peter A., Just, Marianne, Hanusch, Claus, Hackmann, John, Blohmer, Jens-Uwe, Rhiem, Kerstin, Schmitt, Wolfgang D., Furlanetto, Jenny, Gerber, Bernd, Huober, Jens, Nekljudova, Valentina, von Minckwitz, Gunter and Loibl, Sibylle (2019). NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. J. Clin. Oncol., 37 (25). S. 2226 - 2244. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

This list was generated on Sat Jul 31 05:05:31 2021 CEST.